In today’s briefing:
- Mayne Pharma (MYX AU): This Is A Buy
- [IO Fundamentals 16/2025] Robust China Data and Shrinking IO Inventories
Mayne Pharma (MYX AU): This Is A Buy
- On the 21st Feb 2025, Mayne Pharma (MYX AU), a leader in dermatology and women’s health, entered into a Scheme Implementation Deed with US-based pharmaceutical outfit, Cosette Pharmaceuticals.
- Cosette is offering A$7.40/share, a 37% premium to last close. The Offer has the backing of Mayne’s two largest shareholder, Viburnum and Bruce Mathieson, collectively holding 14.1%.
- Mayne has now revised the Scheme timeline, with completion targeted late June, early July. This is done.
[IO Fundamentals 16/2025] Robust China Data and Shrinking IO Inventories
- China’s economy grew 5.4% in Q1 2025, matching Q4 2024 and beating forecasts, as manufacturers boosted exports ahead of Trump’s tariffs.
- China’s March retail sales (+5.9% YoY) and factory output (+7.7% YoY) beat forecasts, accelerating from Jan-Feb growth as economic recovery gains momentum.
- Iron ore inventories fell further in April, with both SMM and CISA reporting weekly drops. Weather-disrupted port operations tightened supply, supporting prices, though US-China trade tensions add demand uncertainty.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
